Connecticut Medicaid and tirzepatide
Zepbound for weight loss: no. Prior authorization for obstructive sleep apnea in adults 18 and older, with airway pressure treatment and lifestyle program rules. Mounjaro for weight loss: not confirmed. No state document read names Mounjaro. The department's December 2025 GLP-1 list does not include it, and ctdssmap.com, which hosts the bulletins, could not be reached.; for type 2 diabetes Connecticut Medicaid must cover it. Read from Connecticut Department of Social Services documents Nov 6, 2026.
In 2025 Connecticut Medicaid paid for 53,677 tirzepatide prescriptions (Mounjaro, Zepbound), 31% of its GLP-1 prescriptions and 11th of the 50 states and DC. It reimbursed $63.4 million before rebates, $1,181 a prescription against $1,032 nationally.
| Brand | Prescriptions | Medicaid paid | Per Rx |
|---|---|---|---|
| Mounjaro | 50,327 | $59.7 million | $1,186 |
| Zepbound | 3,350 | $3.7 million | $1,112 |
Tirzepatide in the states around Connecticut
| State | Sell tirzepatide, ship there | Cheapest | Medicaid Rx, 2025 | Medicaid, Zepbound for weight loss |
|---|---|---|---|---|
| Connecticut | 17 | $69/moWellmedr | 53,677 | Medicaid Zepbound: No |
| Massachusetts | 16 | $69/moWellmedr | 269,389 | Medicaid Zepbound: No |
| New York | 17 | $69/moWellmedr | 218,875 | Medicaid Zepbound: No |
| Rhode Island | 17 | $69/moWellmedr | 12,587 | Medicaid Zepbound: Not confirmed (KFF) |



